Biologics against Crohn's disease
Crohn's disease (or Crohn's disease) can be stopped by early treatment with drugs biologists, can result in disease remission and heal the intestinal mucosa.
These research findings Sonic (Study of Biologic to immunomodulatory Naive Patients in Crohn's Disease), published by The New England journal of Medicine.
The researchers examined 500 patients (from the USA, Israel and Europe) treated with infliximab, a biological drug. He then noted that the treatment had resulted in 70% of cases, mucosal healing and disease remission.
As experts point out, today's approach against Crohn's disease involves the use of steroids. But these substances, in addition to its efficacy, can cause unpleasant side effects
So, despite all due caution, many doctors look very favorably organic option proposed by SONIC.
For example, favorable treatment to Dr. Silvio Danese, head of the Center for Research and Treatment of inflammatory bowel disease IRCCS Istituto Humanitas Rozzano (MI).
Danish says: "Crohn's disease has its greatest ally in time: every day spent without a fight effectively involves a new lesion, a new complication, a new damage. SONIC The study showed that the disease can be 'and it must stop , changing the therapeutic approach and intervene immediately after diagnosis and after a failure with steroid therapy. The data are clear: over the years we have learned that the steroid and 'a drug that should only be used when initiating treatment and then not possible because 'produces side effects. And today we know that the only azathioprine, immunomodulator used in treating disease, not' can block the progression of the disease. This study takes us one step forward and now we can say that use more 'early infliximab alone or in combination, and' patients' right '(ie' those with moderate to severe form), the way to go. " Furthermore, the biological therapy is also positive for "The NHS: it reduces the need for surgery, thus reducing its hospital admissions, visits, examinations.
On the same wavelength Armuzzi Dr. Alexander, director of 'Complex Operations of Internal Medicine and Gastroenterology, Columbus Integrated Complex University' Cattolica in Rome. Armuzzi explains: "A great progress, because 'in many cases so you get' the regression of the disease and mucosal healing without steroid use, enabling better quality 'of life for patients."